Targeting GPRC5D in multiple myeloma

References

• Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin. 2022 Jan;72(1):7–33.
   PubMed Web of Science ®Google Scholar
• Society. AC. Cancer statistics center. [cited 2023 Oct, 19]. Available from: http://cancerstatisticscenter.cancer.org
   Google Scholar
• Barlogie B, Mitchell A, van Rhee F, et al. Curing myeloma at last: defining criteria and providing the evidence. Blood. 2014 Nov 13;124(20):3043–3051. doi: 10.1182/blood-2014-07-552059
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Kumar S. Multiple Myeloma: Diagnosis and Treatment. Mayo Clin Proc. 2016 Jan;91(1):101–119. doi: 10.1016/j.mayocp.2015.11.007
   PubMed Web of Science ®Google Scholar
• Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014 May;28(5):1122–1128.
   PubMed Web of Science ®Google Scholar
• Vo JN, Wu YM, Mishler J, et al. The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma. Nat Commun. 2022 Jun 29;13(1):3750. doi: 10.1038/s41467-022-31430-0
   PubMed Web of Science ®Google Scholar
• Magrangeas F, Avet-Loiseau H, Gouraud W, et al. Minor clone provides a reservoir for relapse in multiple myeloma. Leukemia. 2013 Feb;27(2):473–481.
   PubMed Web of Science ®Google Scholar
• Gandhi UH, Cornell RF, Lakshman A, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019 Sep;33(9):2266–2275.
   PubMed Web of Science ®Google Scholar
• Piron B, Costes-Tertrais D, Gastinne T, et al. Quad-class exposed/refractory myeloma is associated with short survival. Br J Haematol. 2023 Oct 13;204(1):186–190. doi: 10.1111/bjh.19148
   PubMed Web of Science ®Google Scholar
• Roex G, Timmers M, Wouters K, et al. Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma. J Hematol Oncol. 2020 Dec 3;13(1):164. doi: 10.1186/s13045-020-01001-1
   PubMed Web of Science ®Google Scholar
• Moreau P, Touzeau C. T-cell-redirecting bispecific antibodies in multiple myeloma: a revolution? Blood. 2022 Jun 30;139(26):3681–3687.
   PubMed Web of Science ®Google Scholar
• Hou J, Li Y, Lin Q. Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting. Exp Hematol Oncol. 2023 Aug 26;12(1):74.
   PubMed Web of Science ®Google Scholar
• Brinkmann U, Kontermann RE. The making of bispecific antibodies. MAbs. 2017 Feb;9(2):182–212. doi: 10.1080/19420862.2016.1268307
   PubMed Web of Science ®Google Scholar
• Hosoya H, Sidana S. Antibody-based treatment approaches in multiple myeloma. Curr Hematol Malig Rep. 2021 Apr;16(2):183–191. doi: 10.1007/s11899-021-00624-6
   PubMed Web of Science ®Google Scholar
• Lee L, Bounds D, Paterson J, et al. Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma. Br J Haematol. 2016 Sep;174(6):911–922.
   PubMed Web of Science ®Google Scholar
• Verkleij CPM, Broekmans MEC, van Duin M, et al. Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma. Blood Adv. 2021 Apr 27;5(8):2196–2215. doi: 10.1182/bloodadvances.2020003805
   PubMed Web of Science ®Google Scholar
• Carpenter RO, Evbuomwan MO, Pittaluga S, et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin Cancer Res. 2013 Apr 15;19(8):2048–2060. doi: 10.1158/1078-0432.CCR-12-2422
   PubMed Web of Science ®Google Scholar
• Munshi NC, Anderson LD, Shah N, et al. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2021;384(8):705–716. doi: 10.1056/NEJMoa2024850
   PubMed Web of Science ®Google Scholar
• Martin T, Usmani SZ, Berdeja JG, et al. Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up. J Clin Oncol. 2023 Feb 20;41(6):1265–1274. doi: 10.1200/JCO.22.00842
   PubMed Web of Science ®Google Scholar
• Rodriguez-Otero P, Ailawadhi S, Arnulf B, et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med. 2023 Mar 16;388(11):1002–1014. doi: 10.1056/NEJMoa2213614
   PubMed Web of Science ®Google Scholar
• San-Miguel J, Dhakal B, Yong K, et al. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. N Engl J Med. 2023;389(4):335–347. doi: 10.1056/NEJMoa2303379
   PubMed Web of Science ®Google Scholar
• Usmani SZ, Berdeja JG, Madduri D, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed/refractory multiple myeloma (R/R MM): Updated results from CARTITUDE-1. J Clin Oncol. 2021 May 20;39(15_suppl):8005–8005. doi: 10.1200/JCO.2021.39.15_suppl.8005
   Web of Science ®Google Scholar
• Moreau P, Garfall AL, van de Donk NWCJ, et al. Teclistamab in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2022;387(6):495–505. doi: 10.1056/NEJMoa2203478
   PubMed Web of Science ®Google Scholar
• Lesokhin AM, Tomasson MH, Arnulf B, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023 Sep;29(9):2259–2267.
   PubMed Web of Science ®Google Scholar
• Jakubowiak AJ, Bahlis NJ, Raje NS, et al. Elranatamab, a BCMA-targeted T-cell redirecting immunotherapy, for patients with relapsed or refractory multiple myeloma: updated results from MagnetisMM-1. J Clin Oncol. 2022 Jun 01;40(16_suppl):8014–8014. doi: 10.1200/JCO.2022.40.16_suppl.8014
   Web of Science ®Google Scholar
• Samur MK, Fulciniti M, Aktas Samur A, et al. Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nat Commun. 2021 Feb 8;12(1):868. doi: 10.1038/s41467-021-21177-5
   PubMed Web of Science ®Google Scholar
• Li W, Zhang B, Cao W, et al. Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed/refractory multiple myeloma through single-cell sequencing. Exp Hematol Oncol. 2023 May 8;12(1):44. doi: 10.1186/s40164-023-00402-5
   PubMed Web of Science ®Google Scholar
• Cohen YC, Zada M, Wang SY, et al. Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing. Nat Med. 2021 Mar;27(3):491–503.
   PubMed Web of Science ®Google Scholar
• Laurent SA, Hoffmann FS, Kuhn PH, et al. γ-Secretase directly sheds the survival receptor BCMA from plasma cells. Nat Commun. 2015 Jun 11;6(1):7333. doi: 10.1038/ncomms8333
   PubMedGoogle Scholar
• UniProt C. UniProt: the Universal Protein Knowledgebase in 2023. Nucleic Acids Res. 2023 Jan 6;51(D1): D523–D531. doi: 10.1093/nar/gkac1052
   PubMed Web of Science ®Google Scholar
• Xinyi Zhou YY, Hu X, Luo T, et al. Chao Zhang and Juan Du1. Identification Of LPAR1/LPAR5 as novel gpcr partners of GPRC5D for the efficient CAR-T Therapy of multiple myeloma. ASH. 2023;142(Supplement 1):4679–4679. doi: 10.1182/blood-2023-186150
   Google Scholar
• Dacheux MA, Norman DD, Tigyi GJ, et al. Emerging roles of lysophosphatidic acid receptor subtype 5 (LPAR5) in inflammatory diseases and cancer. Pharmacol Ther. 2023 May 01;245:108414.
   PubMed Web of Science ®Google Scholar
• Atamaniuk J, Gleiss A, Porpaczy E, et al. Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma. Eur J Clin Invest. 2012 Sep;42(9):953–960.
   PubMed Web of Science ®Google Scholar
• Smith EL, Harrington K, Staehr M, et al. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci Transl Med. 2019 Mar 27;11(485). doi: 10.1126/scitranslmed.aau7746
   Web of Science ®Google Scholar
• Inoue S, Nambu T, Shimomura T. The RAIG family member, GPRC5D, is associated with hard-keratinized structures. J Invest Dermatol. 2004 Mar;122(3):565–573. doi: 10.1046/j.0022-202X.2004.12628.x
   PubMed Web of Science ®Google Scholar
• Mailankody S, Brentjens RJ, Smith EL. GPRC5D-Targeted CAR T cells for myeloma. Reply N Engl J Med. 2022 Dec 15;387(24):2296.
   PubMed Web of Science ®Google Scholar
• Mei J, Cai Y, Jiang G, et al. GPRC5D as a promising therapeutic target in EGFR-wild and immuno-cold non-small cell lung cancer. J Transl Med. 2023 Aug 13;21(1):542. doi: 10.1186/s12967-023-04415-w
   PubMed Web of Science ®Google Scholar
• Chari A, Minnema MC, Berdeja JG, et al. Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma. N Engl J Med. 2022 Dec 15;387(24):2232–2244. doi: 10.1056/NEJMoa2204591
   PubMed Web of Science ®Google Scholar
• Schinke CD, Touzeau C, Minnema MC, et al. Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed/refractory multiple myeloma (RRMM). J Clin Oncol. 2023;41(16_suppl):8036–8036. doi: 10.1200/JCO.2023.41.16_suppl.8036
   Web of Science ®Google Scholar
• NWCJvd D, Moreau P, Garfall AL, et al. Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM). J Clin Oncol. 2023;41(16_suppl):8011–8011. doi: 10.1200/JCO.2023.41.16_suppl.8011
   Web of Science ®Google Scholar
• Bahlis NJ, Tomasson MH, Mohty M, et al. Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma Naïve to B-Cell maturation antigen (BCMA)-directed therapies: results from cohort a of the magnetismm-3 study. Blood. 2022;140(Supplement 1):391–393. doi: 10.1182/blood-2022-162440
   Google Scholar
• Rodríguez-Otero P, Schinke CD, Chari A, et al. Analysis of infections and parameters of humoral immunity in patients (pts) with relapsed/refractory multiple myeloma (RRMM) treated with talquetamab (tal) monotherapy in MonumenTAL-1. J Clin Oncol. 2023;41(16_suppl):8020–8020. doi: 10.1200/JCO.2023.41.16_suppl.8020
   Web of Science ®Google Scholar
• Mazahreh F, Mazahreh L, Schinke C, et al. Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis. Blood Adv. 2023 Jul 11;7(13):3069–3074. doi: 10.1182/bloodadvances.2022009435
   PubMed Web of Science ®Google Scholar
• Hammons L, Szabo A, Janardan A, et al. The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma. Haematologica. 2023 Aug 31;109(3):906–914. doi: 10.3324/haematol.2023.283590
   Web of Science ®Google Scholar
• Fleischer A, Roll M, Panther F, et al. Taste abnormalities emerging during anti-myeloma therapies including GPRC5D x CD3 bispecific antibody talquetamab. Blood. 2023;142(Supplement 1):2403–2403. doi: 10.1182/blood-2023-186663
   Google Scholar
• Chari A, Oriol A, Krishnan A, et al. Efficacy and safety of less frequent/lower intensity dosing of talquetamab in patients with relapsed/refractory multiple myeloma: results from the phase 1/2 MonumenTAL-1 study. Blood. 2023;142(Supplement 1):1010–1010. doi: 10.1182/blood-2023-181228
   Google Scholar
• Cohen YC, Moreau P, Tolbert J, et al. MonumenTAL-3: phase 3 trial of talquetamab + daratumumab ± pomalidomide versus daratumumab + pomalidomide + dexamethasone in Relapsed/Refractory multiple myeloma following ≥1 prior line of therapy. Blood. 2022;140(Supplement 1):4418–4419. doi: 10.1182/blood-2022-162733
   Google Scholar
• Carlo-Stella C, Mazza R, Manier S, et al. RG6234, a GPRC5DxCD3 T-Cell engaging bispecific antibody, is highly active in patients (pts) with relapsed/refractory multiple myeloma (RRMM): updated intravenous (IV) and first subcutaneous (SC) results from a phase I dose-escalation study. Blood. 2022;140(Supplement 1):397–399. doi: 10.1182/blood-2022-157988
   Google Scholar
• Wang B, Huang X, Sun J, et al. Lbl-034, a highly differentiated T-Cell engaging bispecific antibody targeting GPRC5D for the treatment of relapsed or refractory multiple myeloma. Blood. 2023;142(Supplement 1):4672–4672. doi: 10.1182/blood-2023-181395
   Google Scholar
• Bal S, Htut M, Nadeem O, et al. BMS-986393 (CC-95266), a G protein-coupled receptor class c group 5 member D (GPRC5D)-targeted chimeric antigen receptor (CAR) T-Cell therapy for relapsed/refractory multiple myeloma (RRMM): updated results from a phase 1 study. Blood. 2023;142(Supplement 1):219–219. doi: 10.1182/blood-2023-181857
   Google Scholar
• Bal S, Berdeja J, Htut M, et al. S193: BMS-986393 (CC-95266), AG protein–coupled receptor class C group 5 member D (GPRC5D)–targeted CAR T-cell therapy for relapsed/refractory multiple myeloma (RRMM): results from a phase 1 study. Hemasphere. 2023 Aug 8; 7(Suppl):e9863287. doi: 10.1097/01.HS9.0000967684.98632.87
   Google Scholar
• Mailankody S, Devlin SM, Landa J, et al. GPRC5D-Targeted CAR T cells for myeloma. N Engl J Med. 2022;387(13):1196–1206. doi: 10.1056/NEJMoa2209900
   PubMed Web of Science ®Google Scholar
• Zhang M, Wei G, Zhou L, et al. GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial. Lancet Haematol. 2023 Feb;10(2):e107–e116.
   PubMed Web of Science ®Google Scholar
• Xia J, Li H, Yan Z, et al. Anti–G protein–coupled receptor, class C group 5 member D chimeric antigen receptor T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase II trial. J Clin Oncol. 2023;41(14):2583–2593. doi: 10.1200/JCO.22.01824
   PubMed Web of Science ®Google Scholar
• Mi X, Penson A, Abdel-Wahab O, et al. Genetic basis of relapse after GPRC5D-Targeted CAR T cells. N Engl J Med. 2023 Oct 12;389(15):1435–1437. doi: 10.1056/NEJMc2308544
   PubMed Web of Science ®Google Scholar
• Lee H, Ahn S, Maity R, et al. Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma. Nat Med. 2023 Sep;29(9):2295–2306.
   PubMed Web of Science ®Google Scholar
• Derrien J, Gastineau S, Frigout A, et al. Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivation. Nat Cancer. 2023 Aug 31;4(11):1536–1543. doi: 10.1038/s43018-023-00625-9
   PubMedGoogle Scholar
• Han S, Munawar U, Haertle L, et al. Functional characterization of GPRC5D alteration and its impact on talquetamab resistance in relapsed/refractory multiple myeloma. Blood. 2023;142(Supplement 1):3323–3323. doi: 10.1182/blood-2023-181607
   Google Scholar
• Dekhtiarenko I, Lelios I, Jacob W, et al. Co-expression of GPRC5D, FcRH5 and BCMA suggests that targeting more than one cell surface marker may be a viable strategy in relapsed/refractory multiple myeloma (RRMM): biomarker results from the phase i study of forimtamig, a GPRC5DxCD3 bispecific antibody. Blood. 2023;142(Supplement 1):1948–1948.
   Google Scholar
• Pillarisetti R, Yang D, Yao J, et al. Characterization of JNJ-79635322, a novel BCMAxGPRC5DxCD3 T-Cell redirecting trispecific antibody, for the treatment of multiple myeloma. Blood. 2023;142(Supplement 1):456–456. doi: 10.1182/blood-2023-174941
   Google Scholar
• Dholaria BR, Weisel K, Mateos M-V, et al. Talquetamab (tal) + daratumumab (dara) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Updated TRIMM-2 results. J Clin Oncol. 2023;41(16_suppl):8003–8003. doi: 10.1200/JCO.2023.41.16_suppl.8003
   Google Scholar
• Cohen YC, Morillo D, Gatt ME, et al. First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM). J Clin Oncol. 2023;41(16_suppl):8002–8002. doi: 10.1200/JCO.2023.41.16_suppl.8002
   Web of Science ®Google Scholar
• Matous J, Biran N, Perrot A, et al. Talquetamab + pomalidomide in patients with relapsed/refractory multiple myeloma: safety and preliminary efficacy results from the phase 1b MonumenTAL-2 study. Blood. 2023;142(Supplement 1):1014–1014. doi: 10.1182/blood-2023-187706
   Google Scholar